To include your compound in the COVID-19 Resource Center, submit it here.

Obsidian raises $49.5M series A

After two years in stealth mode, Obsidian Therapeutics Inc. (Cambridge, Mass.) emerged with a $49.5 million series A round led by GV.

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE